352 related articles for article (PubMed ID: 27626685)
81. Change in sonographic brightness can predict pathological response of triple-negative breast cancer to neoadjuvant chemotherapy.
Matsuda N; Kida K; Ohde S; Suzuki K; Yamauchi H; Nakamura S; Tsunoda H
Breast Cancer; 2018 Jan; 25(1):43-49. PubMed ID: 28536943
[TBL] [Abstract][Full Text] [Related]
82. Combined immune checkpoint blockade as a therapeutic strategy for
Nolan E; Savas P; Policheni AN; Darcy PK; Vaillant F; Mintoff CP; Dushyanthen S; Mansour M; Pang JB; Fox SB; ; Perou CM; Visvader JE; Gray DHD; Loi S; Lindeman GJ
Sci Transl Med; 2017 Jun; 9(393):. PubMed ID: 28592566
[TBL] [Abstract][Full Text] [Related]
83. Frequently increased epidermal growth factor receptor (EGFR) copy numbers and decreased BRCA1 mRNA expression in Japanese triple-negative breast cancers.
Toyama T; Yamashita H; Kondo N; Okuda K; Takahashi S; Sasaki H; Sugiura H; Iwase H; Fujii Y
BMC Cancer; 2008 Oct; 8():309. PubMed ID: 18950515
[TBL] [Abstract][Full Text] [Related]
84. A predictor of pathological complete response to neoadjuvant chemotherapy in triple-negative breast cancer patients with the DNA repair genes.
Huang L; Lang GT; Liu Q; Shi JX; Shao ZM; Cao AY
Ann Transl Med; 2021 Feb; 9(4):301. PubMed ID: 33708928
[TBL] [Abstract][Full Text] [Related]
85. The value of platinum agents as neoadjuvant chemotherapy in triple-negative breast cancers: a systematic review and meta-analysis.
Petrelli F; Coinu A; Borgonovo K; Cabiddu M; Ghilardi M; Lonati V; Barni S
Breast Cancer Res Treat; 2014 Apr; 144(2):223-32. PubMed ID: 24557340
[TBL] [Abstract][Full Text] [Related]
86. Biomarkers of DNA Repair and Related Pathways: Significance of Treatment in Triple-Negative Breast Cancer.
Guo W; Lin L; He X; He F; Wang C; Chen N; Wang Y
Crit Rev Oncog; 2017; 22(5-6):427-437. PubMed ID: 29604922
[TBL] [Abstract][Full Text] [Related]
87. Nuclear basic fibroblast growth factor regulates triple-negative breast cancer chemo-resistance.
Li S; Payne S; Wang F; Claus P; Su Z; Groth J; Geradts J; de Ridder G; Alvarez R; Marcom PK; Pizzo SV; Bachelder RE
Breast Cancer Res; 2015 Jul; 17(1):91. PubMed ID: 26141457
[TBL] [Abstract][Full Text] [Related]
88. Magnetic resonance examination to predict pathological complete response following neoadjuvant chemotherapy: when is it appropriate for HER2-positive and triple-negative breast cancers?
Okamoto S; Yamada T; Kanemaki Y; Kojima Y; Tsugawa K; Nakajima Y
Breast Cancer; 2016 Sep; 23(5):789-96. PubMed ID: 26437647
[TBL] [Abstract][Full Text] [Related]
89. Phase II Study With Epirubicin, Cisplatin, and Infusional Fluorouracil Followed by Weekly Paclitaxel With Metronomic Cyclophosphamide as a Preoperative Treatment of Triple-Negative Breast Cancer.
Cancello G; Bagnardi V; Sangalli C; Montagna E; Dellapasqua S; Sporchia A; Iorfida M; Viale G; Barberis M; Veronesi P; Luini A; Intra M; Goldhirsch A; Colleoni M
Clin Breast Cancer; 2015 Aug; 15(4):259-65. PubMed ID: 25933934
[TBL] [Abstract][Full Text] [Related]
90. Mechanisms of Therapy Resistance in Patient-Derived Xenograft Models of BRCA1-Deficient Breast Cancer.
Ter Brugge P; Kristel P; van der Burg E; Boon U; de Maaker M; Lips E; Mulder L; de Ruiter J; Moutinho C; Gevensleben H; Marangoni E; Majewski I; Józwiak K; Kloosterman W; van Roosmalen M; Duran K; Hogervorst F; Turner N; Esteller M; Cuppen E; Wesseling J; Jonkers J
J Natl Cancer Inst; 2016 Nov; 108(11):. PubMed ID: 27381626
[TBL] [Abstract][Full Text] [Related]
91. Next generation sequencing of triple negative breast cancer to find predictors for chemotherapy response.
Lips EH; Michaut M; Hoogstraat M; Mulder L; Besselink NJ; Koudijs MJ; Cuppen E; Voest EE; Bernards R; Nederlof PM; Wesseling J; Rodenhuis S; Wessels LF;
Breast Cancer Res; 2015 Oct; 17(1):134. PubMed ID: 26433948
[TBL] [Abstract][Full Text] [Related]
92. Triple negative breast cancer: looking for the missing link between biology and treatments.
Palma G; Frasci G; Chirico A; Esposito E; Siani C; Saturnino C; Arra C; Ciliberto G; Giordano A; D'Aiuto M
Oncotarget; 2015 Sep; 6(29):26560-74. PubMed ID: 26387133
[TBL] [Abstract][Full Text] [Related]
93. The CDK1 inhibitor RO3306 improves the response of BRCA-proficient breast cancer cells to PARP inhibition.
Xia Q; Cai Y; Peng R; Wu G; Shi Y; Jiang W
Int J Oncol; 2014 Mar; 44(3):735-44. PubMed ID: 24378347
[TBL] [Abstract][Full Text] [Related]
94. Radiosensitization with combined use of olaparib and PI-103 in triple-negative breast cancer.
Jang NY; Kim DH; Cho BJ; Choi EJ; Lee JS; Wu HG; Chie EK; Kim IA
BMC Cancer; 2015 Mar; 15():89. PubMed ID: 25884663
[TBL] [Abstract][Full Text] [Related]
95. AKT1
Kabraji S; Solé X; Huang Y; Bango C; Bowden M; Bardia A; Sgroi D; Loda M; Ramaswamy S
Breast Cancer Res; 2017 Aug; 19(1):88. PubMed ID: 28764807
[TBL] [Abstract][Full Text] [Related]
96. Triple-negative breast cancer: molecular subtypes and targeted therapy.
Hirshfield KM; Ganesan S
Curr Opin Obstet Gynecol; 2014 Feb; 26(1):34-40. PubMed ID: 24346128
[TBL] [Abstract][Full Text] [Related]
97. Pathological complete response as a surrogate for relapse-free survival in patients with triple negative breast cancer after neoadjuvant chemotherapy.
Li J; Chen S; Chen C; Di G; Liu G; Wu J; Shao Z
Oncotarget; 2017 Mar; 8(11):18399-18408. PubMed ID: 27191991
[TBL] [Abstract][Full Text] [Related]
98. Hyperthermia-mediated drug delivery induces biological effects at the tumor and molecular levels that improve cisplatin efficacy in triple negative breast cancer.
Dunne M; Dou YN; Drake DM; Spence T; Gontijo SML; Wells PG; Allen C
J Control Release; 2018 Jul; 282():35-45. PubMed ID: 29673642
[TBL] [Abstract][Full Text] [Related]
99. Genetics of triple-negative breast cancer: Implications for patient care.
Afghahi A; Telli ML; Kurian AW
Curr Probl Cancer; 2016; 40(2-4):130-140. PubMed ID: 28340968
[TBL] [Abstract][Full Text] [Related]
100. Cisplatin-resistant triple-negative breast cancer subtypes: multiple mechanisms of resistance.
Hill DP; Harper A; Malcolm J; McAndrews MS; Mockus SM; Patterson SE; Reynolds T; Baker EJ; Bult CJ; Chesler EJ; Blake JA
BMC Cancer; 2019 Nov; 19(1):1039. PubMed ID: 31684899
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
